

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
30 July 2020 (30.07.2020)



(10) International Publication Number
WO 2020/154571 A8

(51) International Patent Classification:

C07D 413/14 (2006.01) C07D 413/12 (2006.01)
C07D 413/06 (2006.01)

(21) International Application Number:

PCT/US2020/014910

(22) International Filing Date:

24 January 2020 (24.01.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/796,411 24 January 2019 (24.01.2019) US
62/822,353 22 March 2019 (22.03.2019) US
62/934,900 13 November 2019 (13.11.2019) US

(71) Applicant: **YUMANITY THERAPEUTICS, INC.**
[US/US]; 790 Memorial Drive, Suite 2C, Cambridge, MA
02139 (US).

(72) Inventors: **WRONA, Iwona**; c/o Yumanity Therapeu-
tics, Inc., 790 Memorial Drive, Suite 2C, Cambridge, MA
02139 (US). **OZBOYA, Kerem**; c/o Yumanity Therapeu-
tics, Inc., 790 Memorial Drive, Suite 2C, Cambridge, MA
02139 (US). **LUCAS, Matthew**; c/o Yumanity Therapeu-
tics, Inc., 790 Memorial Drive, Suite 2C, Cambridge, MA
02139 (US). **PANDYA, Bhaumik**; c/o Yumanity Thera-
peutics, Inc., 790 Memorial Drive, Suite 2C, Cambridge,
MA 02139 (US). **LE BOURDONNEC, Bertrand**; c/o Yu-
manity Therapeutics, Inc., 790 Memorial Drive, Suite 2C,
Cambridge, MA 02139 (US).

(74) Agent: **BELLIVEAU, Michael J.**; Clark & Elbing LLP,
101 Federal Street, 15th Floor, Boston, MA 02110 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(48) Date of publication of this corrected version:

10 September 2020 (10.09.2020)

(15) Information about Correction:

see Notice of 10 September 2020 (10.09.2020)

(54) Title: COMPOUNDS AND USES THEREOF

(57) Abstract: The present invention features compounds useful in the treatment of neurological disorders and primary brain cancer. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological disorders and primary brain cancer.